These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7557620)

  • 1. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
    Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
    Deshane J; Siegal GP; Wang M; Wright M; Bucy RP; Alvarez RD; Curiel DT
    Gynecol Oncol; 1997 Mar; 64(3):378-85. PubMed ID: 9062138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
    Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
    Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
    Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
    Grim J; Deshane J; Feng M; Lieber A; Kay M; Curiel DT
    Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted tumor killing via an intracellular antibody against erbB-2.
    Deshane J; Siegal GP; Alvarez RD; Wang MH; Feng M; Cabrera G; Liu T; Kay M; Curiel DT
    J Clin Invest; 1995 Dec; 96(6):2980-9. PubMed ID: 8675670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo.
    Stackhouse MA; Buchsbaum DJ; Grizzle WE; Bright SJ; Olsen CC; Kancharla S; Mayo MS; Curiel DT
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):817-22. PubMed ID: 9845103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
    Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line.
    Pupa SM; Howard CM; Invernizzi AM; De Vecchi R; Giani C; Claudio PP; Colnaghi MI; Giordano A; Ménard S
    Oncogene; 1999 Jan; 18(3):651-6. PubMed ID: 9989815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice].
    Li Y; Chang XH; Cui H; Yang WL; Feng J; Wei LH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):451-6. PubMed ID: 12974094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
    Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
    Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.